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• The price of the product should reflect the improvement in
patient outcomes. About $55,000 per annum for a novel
therapy is the current US benchmark, and Euro 55.000
per quality-adjusted life year (or progression-free year) is
probably a reasonable assumption about the practical price
limit in Europe. In the United States, patient assistance
programs and co-pay assistance can help patients obtain
reimbursement and minimise the possibility that co-pay-
ments would limit use. For Europe, a pharmacoeconomic
study is needed.
Increasing cost containment is already taking place in both
Europe and the United States.
When considering clinical trial design, appropriately sized
patient subgroups with a higher likelihood of a treatment benefit
should be prospectively defined to increase the likelihood of a
positive outcome of the study. Furthermore, clinical end-points,
the efficacy improvement required in the treatment arm and
the control arm selected should all be considered with pharmaco-
economic and reimbursement relevance in mind. Ideally, future
pivotal trials should include a built-in pharmacoeconomic
assessment.
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Pancreatic cancer is the fourth leading cause of cancer death and
has a median overall survival of 6 months. The median progres-
sion-free survival time (PFS) is 3 months. One-year overall sur-
vival is about 19%, and the 5-year overall survival is about 2%.
Gemcitabine used to be the only approved agent for treating the
disease in the European Union.
Both epidermal growth factor receptor (EGFR) and Her-2/neu
are overexpressed, activated, or both in most pancreatic cancers1
In vitro data and animal models support EGFR as a potentially
promising agent in pancreatic cancer,2 providing a rationale for
use of erlotinib (Tarceva), an orally available, reversible tyrosine
kinase inhibitor of EGFR.
A phase III trial of erlotinib plus gemcitabine compared with
gemcitabine monotherapy in patients with advanced pancreatic
cancer3 revealed no significant difference in the sum of complete
responses plus partial responses, but a difference was detected
when stable disease was also considered. A comparison of overall
survival in the two study arms revealed little difference, but PFS
was slightly but significantly improved among patients receiving
the combination therapy. The advantage in PFS became apparent
at 3–4 months of treatment, after which the curves for both study
arms were parallel (Fig. 1).
In sum, the combination of erlotinib plus gemcitabine
improved overall survival by about 12 days by delaying progres-
sion of disease. Side effects such as rash and diarrhoea were more
common in the combination-therapy group, but grade 3 or 4 tox-
icities were rare in both groups. Interestingly, patients who
received combination therapy and experienced skin toxicity
exceeding grade1 in severity had better overall and 1-year sur-
vival.3 Exploratory subpopulation analyses suggest that patients
in generally good condition or with distant metastases may
derive enhanced survival benefit.
Fig. 1 – Cost is of lower priority compared with clinical measures for oncologists and payers (chart on left) when it comes to
choosing therapies. The right-hand figure shows relative importance of various factors considered by payers making decisions
about treatment coverage.2
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Both the study design and results can be criticised, noting that
the benefit conferred by the erlotinib and gemcitabine combina-
tion therapy was very limited (i.e., 12 days). No tumour biopsies
were taken to discern which patient subgroups might benefit
more from the addition of erlotinib to their treatment regimens.
Certain subgroups appear to have increased overall survival with
the combination therapy (those who experiencePgrade 1 rash or
have distant metastases), but this aspect of the study was not suf-
ficiently powered to explore possible correlations via subgroup
analyses. Also, exploratory subpopulation analyses have not been
the basis for further confirmatory studies.
Ultimately, both the FDA and EMEA approved the erlotinib–
gemcitabine combination therapy. Committee members strug-
gled with whether such a small survival improvement – which
could be accompanied by an increase in diarrhea and skin rash
– was enough to justify an approval recommendation. In the
end, most committee members agreed that the approval would
be an important ‘first step’ toward new options for what is an
almost uniformly fatal form of cancer’.4
Several questions were posed for the BDA delegates’
consideration:
• Is a median survival advantage of 12 days a clinically relevant
benefit in pancreatic cancer?
• Is there a positive balance between benefit and risk?
• Which is the most relevant endpoint in the demonstrated
study design (overall survival, PFS, relative risk)? Is the pri-
mary endpoint of overall survival the most meaningful in this
setting?
• Can therapy decisions be based on initial side effects as a sur-
rogate marker for survival?
• Which translational research data would have been of rele-
vance for a better study design to avoid ineffective treatments
in nonresponding patients?
It was acknowledged that the shape of the survival curves says
a great deal about the effect of the drug combination; given the
hazard ratio, the benefit appears to translate to 5 or 6 weeks, a
clinically relevant benefit. But the advantage seems to be limited
to a particular subset of patients. The lack of translational
research connected to the clinical trial seems to represent a lost
opportunity. It would have been interesting to examine more
closely which patients derived benefit from the erlotinib–
gemcitabine combination. Also of note, a patient must be alive
to experience drug side effects, such as rash. Thus one would
certainly expect a correlation between side effects and
survival.
L. Bergmann underscored the necessity of undertaking a
risk–benefit analysis when considering whether to approve a
drug. To a patient with pancreatic cancer, is living another 12 days
in such a situation really worth the risks of treatment? Fox,
speaking as a patient advocate, said that another 12 days, even
with diarrhoea and rash, might be very compelling to some
patients. It is of critical importance to provide clear, forth-
right information to patients so that they can make such
decisions.
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Fig. 1 – One-year overall survival of patients on gemcitabine
plus erlotinib compared with gemcitabine monotherapy.3
OS = overall survival; HR = hazard ratio, KI = confidence inter-
val. Reproduced from J Clin Oncol 2007;25(15):1960–6.
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